Kaken Pharmaceutical Co. Overview

  • Founded
  • 1948

Founded
  • Status
  • Public

  • Employees
  • 1,377

Employees
  • Stock Symbol
  • 4521

Stock Symbol
  • Investments
  • 1

  • Share Price
  • $28.19

  • (As of Friday Closing)

Kaken Pharmaceutical Co. General Information

Description

Kaken Pharmaceutical Co is a specialty and generic drug manufacturing company. The company organizes its segments between pharmaceutical and real estate activities. The pharmaceutical segment consists of pharmaceutical drugs, medical devices, and agrochemicals. In the real estate segment, the majority of revenue is generated through commercial facility rental fees. Sales in Japan constitute more than 90% of revenue. Kaken considers merger and acquisition investment to be a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Contact Information

Website
www.kaken.co.jp
Ownership Status
Publicly Held
Financing Status
Corporation
Primary Industry
Pharmaceuticals
Stock Exchange
TKS
Primary Office
  • 2-28-8 Honkomagome, Bunkyo-ku
  • Tokyo, 113-8650
  • Japan

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Kaken Pharmaceutical Co. Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$28.19 $28.68 $24.90 - $37.36 $1.06B 37.5M 59.3K $1.88

Kaken Pharmaceutical Co. Financials Summary

In Thousands,
USD
TTM 30-Sep-2022 FY 2022 31-Mar-2022 FY 2021 31-Mar-2021 FY 2020 31-Mar-2020
EV 482,468 661,940 877,261 1,261,248
Revenue 604,896 676,801 707,086 820,675
EBITDA 122,072 145,821 197,889 265,919
Net Income 70,660 84,998 126,415 178,144
Total Assets 1,158,133 1,353,411 1,480,588 1,460,817
Total Debt 26,650 31,545 34,900 35,624
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Kaken Pharmaceutical Co. Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Kaken Pharmaceutical Co.‘s full profile, request access.

Request a free trial

Kaken Pharmaceutical Co. Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Kaken Pharmaceutical Co is a specialty and generic drug manufacturing company. The company organizes its segments betwee
Pharmaceuticals
Tokyo, Japan
1,377 As of 2022
00000000

000000

dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident,
000000000000000
Hyderabad, India
00000 As of 0000
00000
000000000 00000

000000

smod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
000000000000000
Lagos, Nigeria
00 As of 0000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Kaken Pharmaceutical Co. Competitors (14)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Aurobindo Pharma Corporation Hyderabad, India 00000 00000 000000000 00000
000000000000000 00 Corporation Lagos, Nigeria 00
000000000 Corporation Mumbai, India 0000 000000000
000 00000000000000 Corporation Mumbai, India 00000 000000000000
00. 00000'0 000000 Corporation Hyderabad, India 00000 00000 00000000000 00000
You’re viewing 5 of 14 competitors. Get the full list »

Kaken Pharmaceutical Co. Patents

Kaken Pharmaceutical Co. Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-3174550-A1 Medicament containing sofpironium bromide Pending 03-Mar-2020 00000000
JP-2021138690-A Novel pharmaceutical comprising heteroaromatic amide derivative or salt thereof Pending 28-Feb-2020
EP-3972955-A1 Crystalline form of sofpironium bromide and preparation method thereof Pending 23-May-2019 0000000000
JP-6748329-B1 Crystal form of sofupyronium bromide and method for producing the same Active 23-May-2019 0000000000
JP-2020189839-A Crystalline form of sofpironium bromide and preparation method thereof Active 23-May-2019 C07D207/12 0
To view Kaken Pharmaceutical Co.’s complete patent history, request access »

Kaken Pharmaceutical Co. Executive Team (1)

Name Title Board Seat Contact Info
Hiroyuki Horiuchi Board Member & President
To view Kaken Pharmaceutical Co.’s complete executive team members history, request access »

Kaken Pharmaceutical Co. Board Members (3)

Name Representing Role Since
00000000 00000000 Kaken Pharmaceutical Co. Board Member & President 000 0000
000000 000000000 Kaken Pharmaceutical Co. Board Member 000 0000
00000000 00000 Kaken Pharmaceutical Co. Board Member 000 0000
To view Kaken Pharmaceutical Co.’s complete board members history, request access »

Kaken Pharmaceutical Co. Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Kaken Pharmaceutical Co. Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000 000000 13-Dec-2021 0000000000 Drug Discovery
To view Kaken Pharmaceutical Co.’s complete acquisitions history, request access »

Kaken Pharmaceutical Co. ESG

Risk Overview

Risk Rating

Updated January, 17, 2021

34.89 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

00.00

Management

Management is related to actions taken to manage ESG issues

00.00

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

00 of 15,638

Rank

00.00

Percentile

Pharmaceuticals

Industry

00 of 1,008

Rank

00.00

Percentile

Pharmaceuticals

Subindustry

00 of 473

Rank

00.00

Percentile

To view Kaken Pharmaceutical Co.’s complete esg history, request access »